Moderate Evidence
Research Overview
MariTide Research for Obesity
An evidence-based overview of research examining MariTide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 trials demonstrated approximately 20% weight loss at 52 weeks in patients with BMI ≥30 or ≥27 with comorbidities. Weight loss curves showed no plateau at study end. The MARITIME Phase 3 program was initiated in 2025 to confirm efficacy in larger populations over 72 weeks.
Other Peptides Studied for Obesity
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MariTide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.